Neurocognitive Performance and Clinical Changes in Olanzapine-Treated Patients with Schizophrenia

Raquel E. Gur, Christian Kohler, John D Ragland, Steven J. Siegel, Warren B. Bilker, James Loughead, Nick Phend, Ruben C. Gur

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


Diffuse cognitive impairment characterizes patients with schizophrenia throughout the course of illness. The deficits persist despite clinical improvement associated with neuroleptic intervention and are related to outcome. It is unclear whether treatment with atypical agents is associated with improved cognition that relates to symptoms and outcome. Using a set of computerized neurocognitive measures, we evaluated whether the effects of olanzapine are greater than practice effects for specific neurocognitive domains that could provide targets for large-scale randomized studies. We enrolled 19 patients with schizophrenia before initiation of treatment with olanzapine and 6 of them were examined at 6 weeks and 6 months of follow-up. They were compared to 34 healthy participants who enrolled, 24 of whom were evaluated longitudinally. Improvement exceeding practice effects was observed in patients for abstraction and spatial memory and the latter correlated with clinical improvement in negative symptoms. These results suggest that some effects of olanzapine may impact both symptoms and cognitive performance.

Original languageEnglish (US)
Pages (from-to)2029-2036
Number of pages8
Issue number11
StatePublished - Nov 2003
Externally publishedYes


  • Atypical neuroleptics
  • Cognitive deficits
  • Practice effects
  • Schizophrenia
  • Treatment

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'Neurocognitive Performance and Clinical Changes in Olanzapine-Treated Patients with Schizophrenia'. Together they form a unique fingerprint.

Cite this